INT67474

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1996
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 9
Total Number 10
Disease Relevance 5.43
Pain Relevance 3.73

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Golgi apparatus (B3GAT1) carbohydrate metabolic process (B3GAT1)
Anatomy Link Frequency
spinal 1
foot 1
B3GAT1 (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 98 100.00 Very High Very High Very High
agonist 17 99.96 Very High Very High Very High
substance P 107 99.40 Very High Very High Very High
Neuropeptide 2 99.16 Very High Very High Very High
Central nervous system 1 98.76 Very High Very High Very High
Hyperalgesia 13 98.72 Very High Very High Very High
c fibre 33 98.26 Very High Very High Very High
long-term potentiation 45 97.76 Very High Very High Very High
qutenza 9 97.56 Very High Very High Very High
depression 8 96.00 Very High Very High Very High
Disease Link Frequency Relevance Heat
Vomiting 297 99.92 Very High Very High Very High
Increased Venous Pressure Under Development 9 99.24 Very High Very High Very High
Hyperalgesia 15 98.72 Very High Very High Very High
Ganglion Cysts 1 97.76 Very High Very High Very High
Anaplastic Astrocytoma 4 97.32 Very High Very High Very High
Li-fraumeni Syndrome 24 96.48 Very High Very High Very High
Depression 9 96.00 Very High Very High Very High
Anxiety Disorder 2 94.48 High High
Cancer 4 92.32 High High
Neuropathic Pain 4 84.92 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In addition, this C-fiber dependency is likely related to neuropeptide substance P release and activity because blockade of tachykinin NK1 receptors (66.3+/-13.7% inhibition, n=6; P<0.001), and not NK2 receptors (n=4, NS), almost abolished the myogenic response.
Negative_regulation (blockade) of NK1 associated with c fibre, neuropeptide and substance p
1) Confidence 0.57 Published 2004 Journal Circ. Res. Section Abstract Doc Link 15499026 Disease Relevance 0 Pain Relevance 0.60
Blockade of NK2 but not NK1 receptors prevented by 65% the protection evoked by topical capsaicin without affecting capsaicin-induced hyperemia.
Negative_regulation (Blockade) of NK1 associated with qutenza and increased venous pressure under development
2) Confidence 0.41 Published 1996 Journal Am. J. Physiol. Section Abstract Doc Link 8997245 Disease Relevance 0.26 Pain Relevance 0.50
A frequently used model to establish the central nervous system (CNS) activity of tachykinin NK1 receptor antagonists is the inhibition of NK1 agonist-induced foot tapping in gerbils.
Negative_regulation (inhibition) of NK1 in foot associated with antagonist, agonist and central nervous system
3) Confidence 0.41 Published 2001 Journal Eur. J. Pharmacol. Section Abstract Doc Link 11166289 Disease Relevance 0.26 Pain Relevance 0.28
This effect is normally dominant, but NK2 receptor-mediated vasoconstriction can also occur and is augmented when NK1 receptors are blocked.
Negative_regulation (blocked) of NK1 associated with increased venous pressure under development
4) Confidence 0.41 Published 2000 Journal Jpn. J. Pharmacol. Section Abstract Doc Link 11202607 Disease Relevance 0.48 Pain Relevance 0.17
In the present study, blocking spinal NK1 receptors with L-703,606 (5 mM) not only fully blocked LTP induction but rather led to LFS-induced LTD of C-fibre evoked field potentials (Fig 2B; Table 1).
Negative_regulation (blocking) of NK1 in spinal associated with c fibre, li-fraumeni syndrome, depression and long-term potentiation
5) Confidence 0.41 Published 2008 Journal Mol Pain Section Body Doc Link PMC2424039 Disease Relevance 0.95 Pain Relevance 1.04
We also observed desensitization of NK1 receptors in human bronchi, since the magnitude of the contractile response caused by the second application of the NK1-receptor specific agonist was lower than after the first addition, even with a 10-fold higher concentration.
Negative_regulation (desensitization) of NK1 associated with agonist
6) Confidence 0.16 Published 2010 Journal Respir Res Section Body Doc Link PMC2959027 Disease Relevance 0.17 Pain Relevance 0.24
A rapid functional desensitization of NK1 receptors has been reported with SP and specific NK1 receptor agonists in different tissues [51,52] including airways [22].
Negative_regulation (desensitization) of NK1 associated with agonist and substance p
7) Confidence 0.16 Published 2010 Journal Respir Res Section Body Doc Link PMC2959027 Disease Relevance 0.08 Pain Relevance 0.21
Casopitant: a novel NK1-receptor antagonist in the prevention of chemotherapy-induced nausea and vomiting

Chemotherapy-induced nausea and vomiting (CINV) are among the most feared and distressing symptoms experienced by patients with cancer.

Negative_regulation (antagonist) of NK1 associated with cancer, antagonist and vomiting
8) Confidence 0.09 Published 2009 Journal Therapeutics and Clinical Risk Management Section Title Doc Link PMC2697542 Disease Relevance 1.04 Pain Relevance 0.20
Blocking the NK1 receptor lessens vomiting after cisplatin, and a variety of other emetic stimuli (Diemunsch and Grelot 2000).
Negative_regulation (Blocking) of NK1 associated with vomiting
9) Confidence 0.04 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504061 Disease Relevance 1.37 Pain Relevance 0.28
Its antiemetic properties are attributable to aprepitant, which is a selective neurokinin 1 (NK1) receptor antagonist with low affinity for NK2 and NK3 receptors (Watson et al 1998).
Negative_regulation (antagonist) of NK1 associated with antagonist and vomiting
10) Confidence 0.04 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504061 Disease Relevance 0.82 Pain Relevance 0.20

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox